8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 12, 2026)

Filed February 12, 2026For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 12, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily serves as a vehicle to furnish the accompanying press release containing detailed financial and operational performance information. Investors should refer to Exhibit 99.1, the press release itself, for the substantive details of these results, as this 8-K filing does not contain the specific figures but rather points to the document where they can be found. The company is utilizing this filing to meet its disclosure obligations regarding material events, specifically the release of its earnings. While the 8-K itself is brief, the furnished press release (Exhibit 99.1) is expected to contain crucial information regarding Alnylam's revenue performance, profitability, key product sales (such as ONPZEO, GIVLAARI, and OXLUMO), pipeline advancements, and any forward-looking guidance for the upcoming fiscal year. Investors will be keen to understand the company's financial health, operational execution, and strategic direction as outlined in the earnings announcement. It is imperative for stakeholders to review the content of the press release for a comprehensive understanding of Alnylam's recent performance and future outlook.

Key Highlights

  • 1Alnylam Pharmaceuticals (ALNY) announced Q4 and Full Year 2025 financial results on February 12, 2026.
  • 2The 8-K filing primarily furnishes a press release (Exhibit 99.1) containing the detailed financial results.
  • 3Key financial metrics for the quarter and full year ended December 31, 2025, are available in the furnished press release.
  • 4Investors should consult Exhibit 99.1 for specific revenue figures, profitability, and operational performance data.
  • 5The filing confirms the company is adhering to its public disclosure requirements for earnings announcements.
  • 6The press release is expected to include updates on key product sales and pipeline progress.
  • 7No specific financial figures are detailed within the 8-K filing itself; all substantive information is in the press release.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide access to Alnylam Pharmaceuticals' financial results for the fourth quarter and full year ended December 31, 2025. It officially furnishes the press release containing these results as Exhibit 99.1.

The actual financial results, including revenue, earnings, and other key performance indicators, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. You will need to access Exhibit 99.1 for this information.

While the 8-K filing itself does not contain forward-looking guidance, the accompanying press release (Exhibit 99.1) is typically where companies provide such information. Investors should review the press release for any updates on future expectations or guidance.

This statement means that the financial results information furnished under Item 2.02 is generally not subject to the same liability provisions under Section 18 of the Exchange Act as other 'filed' information. It also means it won't be automatically incorporated into future SEC filings unless specifically referenced. However, the information is still considered material disclosure.